BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial

Osteoporosis International

Volumn 16, Issue 8, 2005, Pages 943-952

  Palomba, Stefano ^a,d   Orio Jr , Francesco ^b   Russo, Tiziana ^a   Falbo, Angela ^a   Tolino, Achille ^b   Manguso, Francesco ^b   Nunziata, Vincenzo ^b   Mastrantonio, Pasquale ^c   Lombardi, Gaetano ^b   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d NONE   (Italy)

Author keywords

Bisphosphonates; Clinical trials; Menopause; Osteoporosis; SERMs; Treatments; Vitamin D

Indexed keywords

ALENDRONIC ACID; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DEOXYPYRIDINOLINE; OSTEOCALCIN; RALOXIFENE; VITAMIN D RECEPTOR;

ARTICLE; BLOOD ANALYSIS; BONE DENSITY; BONE MINERAL; BONE TURNOVER; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DNA DETERMINATION; DRUG EFFICACY; DRUG FATALITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HEART INFARCTION; HORMONAL THERAPY; HOT FLUSH; HUMAN; LEG CRAMP; LUMBAR SPINE; MAJOR CLINICAL STUDY; MASTALGIA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PHARMACOGENETICS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESTRICTION MAPPING; SIDE EFFECT; STOMACH PAIN; STYPSIS; URINALYSIS; UTERUS BLEEDING; UTERUS CRAMP; UTERUS DISEASE; VOMITING;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); FEMALE; GENOTYPE; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; RALOXIFENE; RECEPTORS, CALCITRIOL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 23744498096     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-004-1800-5     Document Type: Article

References (43)

1. Sharpe M, Noble S, Spencer MC (2001) Alendronate. An update of its use in osteoporosis. Drugs 61:999-1039
2. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026
3. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HAP, Recker RR, Harris ST, Wu W, Genant HK, Black MD, Eastell R (2002) Efficacy of Raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617
4. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestins in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 17:321-333
5. Marcus R, Wong M, Heath H 3rd, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: Comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 23:16-37
6. Ettinger B, Bilezikian JP (2002) For osteoporosis, are two antiresorptive drugs better than one? J Clin Endocrinol Metab 87:983-984
7. Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, Liss CL, Melton ME, Byrnes CA (1999) Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 84:3076-3081
8. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Stuart RW, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A (2000) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 85:720-726
9. Tiras MB, Noyan V, Yildiz A, Yildirim M, Daya S (2000) Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study. Hum Reprod 15:2087-2092
10. Palomba S, Orio F Jr, Di Carlo C, Colao A, Lombardi G, Zullo F, Mastrantonio P (2002) Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:1502-1058
11. Johnell O, Scheele WH, Yili L, Reginster JY, Need AG, Seeman E (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985-992
12. Greenspan SL, Resnik NM, Parker RA (2003) Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 289:2525-2533
13. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D (2000) Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283:1318-1322
14. Eisman JA (1999) Genetics of osteoporosis. Endocr Rev 20:788-804
15. Eisman JA (2001) Pharmacogenetics of the vitamin D receptor and osteoporosis. Drug Metab Dispos 9:505-512
16. Ferrari S, Rizzoli R, Chavalley T, Slosman D, Eisman JA, Bonjour JP (1995) Vitamin D receptor gene polymorphism and rate of change in lumbar spine bone mineral density in elderly men and women. Lancet 10:423-426
17. Dawson-Hughes B, Harris SS, Finneran S (1995) Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. J Clin Endocrinol Metab 80:3657-3661
18. Kiel DP, Myers RH, Cupples LA, Kong XF, Zhu XH, Ordovas J, Schaefer EJ, Felson DT, Rush D, Wilson PW (1997) The BsmI vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density. J Bone Miner Res 12:1049-1057
19. Howard G, Nguyen T, Morrison N, Watanabe T, Sambrook P, Eisman J, Kelly PJ (1995) Genetic influence on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J Clin Endocrinol Metab 80:2800-2805
20. Wishart JM, Horowitz M, Need AG, Scopacasa F, Morris HA, Clifton PM, Nordin BE (1997) Relations between calcium intake, calcitriol, polymorphism of the vitamin D receptor gene and calcium adsorption in premenopausal women. Am J Clin Nutr 65:798-802
21. Graafmans WC, Lips P, Ooms ME, van Leeuwen JP, Pols HA, Uitterlinden AG (1997) The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J Bone Miner Res 12:1241-1245
22. Fleisch H (1998) Bisphosphonates: Mechanisms of action. Endocr Rev 19:80-100
23. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanism of action of bisphosphonates. Cancer 88 [Suppl 12]:2961-2978
24. Byrne IM, Flanagan L, Tenniswood MP, Welsh J (2000) Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology 141:2829-2836
25. Ishibe M, Nojima T, Ishibashi T, Koda T, Kaneda K, Rosier RN, Puzas JE (1995) 17 beta-estradiol increases the receptor number and modulates the action of 1, 25-dihydroxyvitamin D3 in human osteosarcoma-derived osteoblast-like cells. Calcif Tissue Int 57:430-435
26. Liel Y, Kraus S, Levy J, Shany S (1992) Evidence that estrogens modulate activity and increase the number of 1, 25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/ 2.8). Endocrinology 130:2597-2601
27. Marc J, Prezelj J, Komel R, Kocijancic A (1999) VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos Int 10:303-306
28. Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V (2003) Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes. Clin Endocrinol (Oxf) 1:22-29
29. Deng HW, Li J, Li JL, Johnson M, Gong G, Davis KM, Recker RR (1998) Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum Genet 103:576-585
30. Kurabayashi T, Tomita M, Matsushita H, Yahata T, Honda A, Takakuwa K, Tanaka K (1999) Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol 180:1115-1120
31. Tofteng CL, Jensen JE, Abrahamsen B, Odum L, Brot C (2002) Two polymorphisms in the vitamin D receptor gene - association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. J Bone Miner Res 17:535-544
32. Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V (2003) Raloxifene administration in postmenopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum Reprod 1:1-7
33. Rand TH, Seidl G, Kainberger F, Resch A, Hittmair K, Schneider B, Gluer CC, Imhof H (1997) Impact of spinal degenerative changes on the evaluation of bone mineral density with dual energy X-ray absorptiometry (DXA). Calcif Tissue Int 60:430-433
34. Orwell ES, Oviatt KS, Mann T (1990) The impact of osteophytic and vascular calcification on vertebral mineral density measurement in men. J Clin Endocrinol Metab 70:1202-1207
35. Masud T, Keen R, Nandra D, Jawed S, Doyle DV, Spector TD (1996) Facet joint osteoarthritis and bone density measurements. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD (eds) Osteoporosis. Elsevier Science, Amsterdam, pp 167-170
36. Kiel D (1995) Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. J Bone Miner Res 10:518-523
37. Sainz J, Van Turnout JM, Loro ML, Sayre J, Roe TF, Gilsanz V (1997) Vitamin D receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. N Engl J Med 337:77-82
38. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA (1994) Prediction of bone density from Vitamin D receptor alleles. Nature 367:284-287
39. Gennari L, Becherini L, Masi L, Mansani R, Gonnelli S, Cepollaro C, Martini S, Montagnani A, Lentini G, Becorpi AM, Brandi ML (1998) Vitamin D end estrogen receptor allelic variants in Italian postmenopausal women: evidence of multiple gene contribution to bone mineral density. J Clin Endocrinol Metab 83:939-944
40. GLM repeated measures (2003) In: SPSS Advanced Models 12.0. SPSS, Chicago, Chapter 2, pp 17-34
41. Egger M, Juni P, Bartlett C; CONSORT Group (Consolidated Standards of Reporting of Trials) (2001) Value of flow diagrams in reports of randomized controlled trials. JAMA 285:1996-1999
42. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289
43. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10